Data gathered: November 14
Alternative Data for Immunoprecise Antibodies
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,297 | Sign up | Sign up | Sign up |
| Twitter Mentions | 36 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Immunoprecise Antibodies
ImmunoPrecise Antibodies Ltd., is engaged in antibody production and related services in the United States, Canada, Europe, and internationally. The company is headquartered in Victoria, Canada.
| Price | $0.46 |
| Target Price | Sign up |
| Volume | 179,620 |
| Market Cap | $13M |
| Year Range | $0.39 - $1.84 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer TherapiesNovember 12 - Yahoo |
 |
Renaissance Technologies LLC Has $65,000 Stock Position in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA)October 15 - ETF Daily News |
 |
ImmunoPrecise Antibodies (OTCMKTS:IPATF) Shares Up 15.2% – Here’s What HappenedOctober 9 - ETF Daily News |
 |
ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ...October 9 - Yahoo |
|
Brokers Issue Forecasts for ImmunoPrecise Antibodies Ltd.’s Q1 2026 Earnings (NASDAQ:IPA)September 19 - ETF Daily News |
|
Q2 2025 EPS Estimates for ImmunoPrecise Antibodies Ltd. Decreased by HC Wainwright (NASDAQ:IPA)September 19 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 5.3M | 2.9M | 2.4M | -4M | -3.2M | -0.110 |
| Q2 '24 | 6.5M | 3.4M | 3.1M | -18M | -2.3M | -0.110 |
| Q1 '24 | 6.2M | 3.2M | 3M | -2.6M | -1.4M | -0.110 |
| Q4 '23 | 6.2M | 3.2M | 3M | -2.6M | -1.4M | -0.100 |
| Q3 '23 | 4.7M | 2.2M | 2.5M | -9.4M | -8.2M | -0.140 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Immunoprecise Antibodies (IPA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Immunoprecise Antibodies?
The Market Cap of Immunoprecise Antibodies is $13M.
What is the current stock price of Immunoprecise Antibodies?
Currently, the price of one share of Immunoprecise Antibodies stock is $0.46.
How can I analyze the IPA stock price chart for investment decisions?
The IPA stock price chart above provides a comprehensive visual representation of Immunoprecise Antibodies' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Immunoprecise Antibodies shares. Our platform offers an up-to-date IPA stock price chart, along with technical data analysis and alternative data insights.
Does IPA offer dividends to its shareholders?
As of our latest update, Immunoprecise Antibodies (IPA) does not offer dividends to its shareholders. Investors interested in Immunoprecise Antibodies should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Immunoprecise Antibodies?
Some of the similar stocks of Immunoprecise Antibodies are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.